Millennium Management’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.15M | Buy |
250,525
+164,724
| +192% | +$5.29M | ﹤0.01% | 2378 |
|
|
2025
Q4 | $3.02M | Sell |
85,801
-341,894
| -80% | -$12.1M | ﹤0.01% | 3550 |
|
|
2025
Q3 | $11.2M | Sell |
427,695
-514,242
| -55% | -$15.3M | ﹤0.01% | 2285 |
|
|
2025
Q2 | $25M | Buy |
941,937
+689,292
| +273% | +$18.1M | 0.01% | 1368 |
|
|
2025
Q1 | $6.1M | Buy |
252,645
+149,913
| +146% | +$4.74M | ﹤0.01% | 2665 |
|
|
2024
Q4 | $4.13M | Sell |
102,732
-69,590
| -40% | -$3.97M | ﹤0.01% | 2994 |
|
|
2024
Q3 | $10.9M | Sell |
172,322
-550,692
| -76% | -$32.3M | 0.01% | 2118 |
|
|
2024
Q2 | $38.3M | Buy |
723,014
+325,925
| +82% | +$21.4M | 0.02% | 976 |
|
|
2024
Q1 | $32.6M | Sell |
397,089
-5,767
| -1% | -$257K | 0.01% | 1140 |
|
|
2023
Q4 | $7.5M | Sell |
402,856
-1,189,838
| -75% | -$15.6M | ﹤0.01% | 2442 |
|
|
2023
Q3 | $17.6M | Sell |
1,592,694
-230,426
| -13% | -$3.3M | 0.01% | 1534 |
|
|
2023
Q2 | $29.6M | Sell |
1,823,120
-2,014,876
| -52% | -$42.2M | 0.01% | 1079 |
|
|
2023
Q1 | $63.9M | Sell |
3,837,996
-544,504
| -12% | -$5.62M | 0.04% | 550 |
|
|
2022
Q4 | $41.2M | Buy |
4,382,500
+1,279,469
| +41% | +$5.71M | 0.02% | 877 |
|
|
2022
Q3 | $8.44M | Buy |
3,103,031
+1,788,275
| +136% | +$5.86M | 0.01% | 2361 |
|
|
2022
Q2 | $3.8M | Sell |
1,314,756
-187,130
| -12% | -$463K | ﹤0.01% | 3068 |
|
|
2022
Q1 | $4.51M | Buy |
1,501,886
+1,296,236
| +630% | +$4.65M | ﹤0.01% | 3049 |
|
|
2021
Q4 | $946K | Buy |
205,650
+146,442
| +247% | +$821K | ﹤0.01% | 4458 |
|
|
2021
Q3 | $372K | Buy |
59,208
+11,532
| +24% | +$71.2K | ﹤0.01% | 5633 |
|
|
2021
Q2 | $286K | Buy |
+47,676
| New | +$283K | ﹤0.01% | 5766 |
|
|
2020
Q4 | – | Sell |
-35,091
| Closed | -$204 | – | 5612 |
|
|
2020
Q3 | $204 | Sell |
35,091
-365,603
| -91% | -$2.52M | ﹤0.01% | 4056 |
|
|
2020
Q2 | $2.89M | Buy |
400,694
+353,447
| +748% | +$2.35M | ﹤0.01% | 2251 |
|
|
2020
Q1 | $221K | Buy |
+47,247
| New | +$290K | ﹤0.01% | 3340 |
|
|
2019
Q4 | – | Sell |
-169,070
| Closed | -$1.16M | – | 4671 |
|
|
2019
Q3 | $1.16M | Buy |
+169,070
| New | +$1.26M | ﹤0.01% | 2761 |
|
|
2019
Q1 | – | Sell |
-82,900
| Closed | -$634K | – | 4362 |
|
|
2018
Q4 | $634K | Sell |
82,900
-286,516
| -78% | -$3.43M | ﹤0.01% | 2814 |
|
|
2018
Q3 | $6.43M | Sell |
369,416
-371,188
| -50% | -$4.42M | 0.01% | 1626 |
|
|
2018
Q2 | $7.03M | Sell |
740,604
-658,766
| -47% | -$4.38M | 0.01% | 1560 |
|
|
2018
Q1 | $6.12M | Buy |
1,399,370
+696,398
| +99% | +$3.85M | 0.01% | 1674 |
|
|
2017
Q4 | $2.85M | Buy |
+702,972
| New | +$2.04M | ﹤0.01% | 2059 |
|
Other funds holding VKTX
VCM
VPM
Millennium Management's VKTX Position: Q1 2026 in Review
Millennium Management increased its Viking Therapeutics (VKTX) stake by 192% in Q1 2026, buying an estimated $5.29M and bringing the position to 250,525 shares worth $8.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2378.
Millennium Management first reported a position in VKTX in Q4 2017 and has held it in 29 quarters since. The position peaked at $63.9M in Q1 2023. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Millennium Management held 250,525 shares of Viking Therapeutics worth $8.15M as of Q1 2026.
- Millennium Management bought 164,724 Viking Therapeutics shares in Q1 2026, an estimated $5.29M.
- Viking Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2378 holding.
- Millennium Management first reported a position in Viking Therapeutics in Q4 2017 and has held it in 29 quarters since.
- Millennium Management's Viking Therapeutics position peaked at $63.9M in Q1 2023.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.